Supporting accelerated growth of R&D, manufacturing, and commercial activities with new 100,000 sq-ft state-of-the-art facility
Reinforcing commitment to the region as Abcam approaches 20 years of US presence
CAMBRIDGE, July 13, 2021 /PRNewswire/ -- Abcam (AIM: ABC) (NASDAQ: ABCM), a global innovator in life
The new facility is a central component of Abcam's growth in the United States, reinforcing its commitment to support the research and biopharma sector globally and serving as a hub for the Company's R&D and commercial activities in the region.
"Abcam's first step toward global expansion was in 2003 at Kendall Square. Since then, the US has become our largest market." commented Alan Hirzel, CEO at Abcam. "Investing in and expanding our presence in the vibrant Greater Boston cluster is another step in our journey to support biopharma partners and life science researchers globally, in their quest to accelerate discovery and the translation of these discoveries into improved human health outcomes."
The 100,000 sq-ft site will increase the Company's flexibility, scale, and capacity in R&D, Production, Distribution, and Customer Service required to address the increasing needs of the life sciences sector. The ability to provide critical reagents to support research in all areas of the life sciences is vital to enable scientific breakthroughs that underpin the rapid development of diagnostics, vaccines, and potential therapeutics.
"Massachusetts continues to attract life sciences companies from across the globe, who come here to access our leading academic and medical institutions, diverse talent, a supportive government, and a robust start-up community," said Kendalle Burlin O'Connell, president and COO at MassBio. "We are thrilled to see Abcam outgrow its presence in Kendall Square and expand to Waltham, an area of growing interest for life sciences companies and one that is positioned for explosive growth in the coming years."
This facility more than doubles Abcam's capacity from its previous site in Kendall Square, Cambridge, MA and is expected to eventually house approximately 300 employees. The opening follows Abcam's listing on NASDAQ in October 2020 and the establishment of its new cell engineering facility in the Bay Area in December 2020.
Notes to Editors
About Abcam plc As a global life sciences company, Abcam identifies, develops, and distributes high-quality biological reagents and tools that are crucial to research, drug discovery and diagnostics. Working across the industry, the Company supports life scientists to achieve their mission, faster.
Abcam partners with life sciences organizations to co-create novel binders for use in drug discovery, in vitro diagnostics and therapeutics, driven by the Company's proprietary discovery platforms and world-leading antibody expertise.
By constantly innovating its binders and assays, Abcam is helping advance the global understanding of biology and causes of disease, which enables new treatments and improved health. The Company's pioneering data-sharing approach gives scientists increased confidence in their results by providing validation, user comments and peer-reviewed citations for its 90,000 products.
With 13 sites globally, many of Abcam's 1,600-strong team are located in the world's leading life sciences research hubs, complementing a global network of services and support.
To find out more, please visit www.abcam.com and www.abcamplc.com.
